Clinical Trial Update: Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 safety study evaluating XL765 (SAR245409) in combination with erlotinib in adults with solid tumors, including…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• XL765 (SAR245409)

Snippet

Sponsor: Sanofi | Conditions: Cancer, Non-Small Cell Lung Cancer | Phase 1 | Status: COMPLETED